O
OliPass Corp
KOSDAQ:244460
OliPass Corp
KOSDAQ:244460
Price:
1 651
KRW
-13.92%
Market Closed
Market Cap:
₩13.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Popular Picks
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
OliPass Corp
PP&E Gross
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
OliPass Corp
PP&E Gross Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | PP&E Gross | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
OliPass Corp
KOSDAQ:244460
|
PP&E Gross
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
PP&E Gross
₩1.7T
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
PP&E Gross
₩50.5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
PP&E Gross
₩6.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
PP&E Gross
₩40.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
PP&E Gross
₩101.1B
|
CAGR 3-Years
147%
|
CAGR 5-Years
90%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
OliPass Corp
Glance View
OliPass Corp. develops biological products. The company is headquartered in Yongin, Gyeonggi-Do. The company went IPO on 2019-09-20. The firm principally manufactures and sells nonopioid analgesic, hyperlipidemia medicine, ocular angiogenesis inhibitor, duchenne dystrophy medicine, cancer immunotherapy medicine and other products. In addition, the Company researches, develops and sells functional cosmetics through the artificial gene platform technology.
Intrinsic Value
1 520.05
KRW
Overvaluation 8%
O
